松坂樹梨[DSEX-001]发行于2008-07-21时长67分钟出品商是ジャネス,DSEX-001作品种子搜索下载,[GTOK-001]发行于2008-09-06时长94分钟出品商是ラハイナ東海,GTOK-001作品种子搜索下载
松坂樹梨[DSEX-001]发行于2008-07-21时长67分钟出品商是ジャネス,DSEX-001作品种子搜索下载,[GTOK-001]发行于2008-09-06时长94分钟出品商是ラハイナ東海,GTOK-001作品种子搜索下载
Galeterone (TOK-001)是一种选择性CYP17抑制剂,也是androgen receptor (AR)(雄激素受体)拮抗剂,IC50分别为300 nM和384 nM,也有效抑制人类前列腺肿瘤生长。Phase 2。 CAS: 851983-85-2 规格价格库存 10mM (1mL in DMSO) RMB 2125.13 现货 5mg RMB 1380.57 现货 25mg RMB 3866.37 现货 50mg RMB 5477.08 ...
Galeterone (TOK-001) 是一种多功能的抗雄激素,是CYP17抑制剂,在去势抵抗性前列腺癌中,IC50为 47 nM。 MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务 我们将采用定制合成服务的方式为您快速提供所需产品和技术服务 GaleteroneChemical Structure ...
In our effort to discover potent and specific inhibitors of 17α-hydroxylase/17,20-lyase (CYP17), the key enzyme which catalyzes the biosynthesis of androgens from progestins, 3β-(hydroxy)-17-(1H-benzimidazole-1-yl)androsta-5,16-diene (Galeterone or TOK-001, formerly called VN/124-1) ...
P450 (e.g. CYP)Galeterone 中文名称: 加来特龙; 伽来特隆 别名: Galeterone; NX41765; NX 41765; TOK001; NX-41765; VN 1241; TOK-001; TOK 001; VN-1241; VN-1241 (3beta)-17-(1H-苯并咪唑-1-基)-5,16-雄二烯-3-醇; (3beta)-17-(1H-苯并咪唑-1-基)雄甾-5,16-二烯-3-醇; Galete...
Gastrointestinal Cancers: Gastric and Esophageal Cancers Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers Genitourinary Oncology Gynecological Oncology Head and Neck Cancer Hematologic Malignancies Molecular and Cellular Oncology Neuro-Oncology and Neurosurgical Oncology Pediatric Oncology Pharmacology of Anti...
M. H. Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. J. Med. Chem. 2015, 58, 2077–2087, DOI: 10.1021/jm501239f Google Scholar 23 Scaffidi, A.; Waters, M. T.; Ghisalberti, E. L.; Dixon, K. W.; Flematti...
Structures were obtained in the presence of the steroidal inhibitors abiraterone and TOK-001. The binding mode differs substantially from that predicted by homology models, and is of interest to structural biologists and those involved in developing improved inhibitors as potential therapeutics.show all ...